Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Non interventional study collecting patient reported outcomes. The study aims to assess the disease burden of chronic urticaria patients and to record the therapies used in daily clinical practice in the UK and the impact they have on the quality of life and work productivity of individual patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Measuring responses to PROs from patients on different treatments | Measuring quality of life, work productivity and changes in disease for patients on different treatment. | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| To record use of clinical resources | Measuring how often clinical resources (hospitalisations, frequency of visits) are used | 24 months |
| Previous, current and future medication | Recording medication use throughout the 24 months |
Not provided
Inclusion Criteria:
Subjects must be 18 years old Subject must be willing and able to provide written informed consent for collection and analysis of routine data and PROs Subject must have medically confirmed diagnosis of chronic urticaria present for more than 2 months.
Subject must be refactory to at least one H1 antihistamine
Exclusion Criteria:
Subjects who in the estimation of the treating physician are unlikely to be available for the full duration of the follow-up period of 24 months.
Subjects taking must not take part in any other concurrent urticarial study.
-
Not provided
Not provided
Not provided
Chronic Urticaria Patients
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Plymouth | Devon | PL6 8DH | United Kingdom | ||
| Novartis Investigative Site |
Not provided
Not provided
Not provided
Not provided
| 24 months |
| The disease burden of chronic urticaria | The "disease burden" (including impact on sleep and work productivity) | 24 months |
| Rates of spontaneous remission | 24 months |
| Treatment algorithms and trends | Measuring treatment algorithms and trends during the study course (including therapy adjustments and duration of use of each substance class) | 24 months |
| Co-morbidities of refractory CU patients | 24 months |
| first onset of chronic urticaria | Time of first onset of the disease and number physicians consulted | 24 months |
| Number of patients with angiodema | 24 months |
| Number of angioedema episodes during the observational phase | 24 months |
| Prevalence of inducible urticaria | The number of patients in the study population that are diagnosed with inducible urticaria. | 24 months |
| Diagnosis of CSU | 24 months |
| Darlington |
| Durham |
| DL3 6HX |
| United Kingdom |
| Novartis Investigative Site | Leytonstone | London | E11 1NR | United Kingdom |
| Novartis Investigative Site | Salford | Manchester | M6 8HD | United Kingdom |
| Novartis Investigative Site | Coventry | Warwickshire | CV2 2DX | United Kingdom |
| Novartis Investigative Site | Belfast | BT12 6BA | United Kingdom |
| Novartis Investigative Site | Belfast | BT9 7AB | United Kingdom |
| Novartis Investigative Site | Cardiff | CF14 4XW | United Kingdom |
| Novartis Investigative Site | Chester | CH2 1UL | United Kingdom |
| Novartis Investigative Site | Durham | DH1 6TW | United Kingdom |
| Novartis Investigative Site | East Yorkshire | HU16 5JQ | United Kingdom |
| Novartis Investigative Site | Kent | CT9 4AN | United Kingdom |
| Novartis Investigative Site | Leeds | LS9 7PN | United Kingdom |
| Novartis Investigative Site | Leicester | LE1 5WW | United Kingdom |
| Novartis Investigative Site | Liverpool | L14 3PE | United Kingdom |
| Novartis Investigative Site | London | SE18 4QH | United Kingdom |
| Novartis Investigative Site | Manchester | M13 9WL | United Kingdom |
| Novartis Investigative Site | Manchester | M23 9LT | United Kingdom |
| Novartis Investigative Site | Middlesbrough | TS4 3BW | United Kingdom |
| Novartis Investigative Site | Poole | BH15 2JB | United Kingdom |
| Novartis Investigative Site | Sheffield | S5 7AU | United Kingdom |
| ID | Term |
|---|---|
| D000080223 | Chronic Urticaria |
| ID | Term |
|---|---|
| D014581 | Urticaria |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided